Moderna's potential COVID-19 vaccine generates promising immune response in elderly patients
- 4 years ago
모더나, 노년층 대상 코로나19 백신 실험 성과
Moderna's potential COVID-19 vaccine has reportedly generated a promising immune response in elderly patients in an early stage clinical trial.
The biotech firm said Wednesday that its vaccine was tested on ten adults between the ages of 56 and 70 and ten elderly adults aged 71 and older.
The volunteers produced T-cells and neutralizing antibodies, which researchers believe are necessary to build immunity against the virus.
Additionally, the antibodies that were produced were higher than those seen in people who have recovered from COVID-19.
Moderna's potential COVID-19 vaccine has reportedly generated a promising immune response in elderly patients in an early stage clinical trial.
The biotech firm said Wednesday that its vaccine was tested on ten adults between the ages of 56 and 70 and ten elderly adults aged 71 and older.
The volunteers produced T-cells and neutralizing antibodies, which researchers believe are necessary to build immunity against the virus.
Additionally, the antibodies that were produced were higher than those seen in people who have recovered from COVID-19.